Duke Human Vaccine Institute
-
People
-
Primary Appointments
- Azoitei, Mihai Luchian, Assistant Professor in Medicine
-
Secondary Appointments
- Staats, Herman Ford, Associate Professor of Medicine
-
Memberships
- Acharya, Priyamvada, Member of the Duke Human Vaccine Institute
- Alam, S. Munir, Member of the Duke Human Vaccine Institute
- Azoitei, Mihai Luchian, Member of the Duke Human Vaccine Institute
- Blasi, Maria, Member of the Duke Human Vaccine Institute
- Bonsignori, Mattia, Member of the Duke Human Vaccine Institute
- Bradley, Todd Christopher, Member of the Duke Human Vaccine Institute
- Cain, Derek Wilson, Member of the Duke Human Vaccine Institute
- Denny, Thomas Norton, Member of the Duke Human Vaccine Institute
- Easterhoff, David James, Member of the Duke Human Vaccine Institute
- Edwards, Robert J, Member of the Duke Human Vaccine Institute
- Ferrari, Guido, Member of the Duke Human Vaccine Institute
- Fouda, Genevieve Giny, Member of the Duke Human Vaccine Institute
- Frothingham, Richard, Member of the Duke Human Vaccine Institute
- Gao, Feng, Member of the Duke Human Vaccine Institute
- Hale, Laura Pope, Member of the Duke Human Vaccine Institute
- Haynes, Barton Ford, Member of the Duke Human Vaccine Institute
- Katz, Samuel L., Member of the Duke Human Vaccine Institute
- Kelsoe, Garnett H., Member of the Duke Human Vaccine Institute
- Klotman, Mary E, Member of the Duke Human Vaccine Institute
- Lee, Sunhee, Member of the Duke Human Vaccine Institute
- Liao, Hua-Xin, Member of the Duke Human Vaccine Institute
- Montefiori, David Charles, Member of the Duke Human Vaccine Institute
- Moody, Michael Anthony, Member of the Duke Human Vaccine Institute
- Permar, Sallie Robey, Member of the Duke Human Vaccine Institute
- Pickup, David James, Member of the Duke Human Vaccine Institute
- Pisetsky, David Stephen, Member of the Duke Human Vaccine Institute
- Pollara, Justin Joseph, Member of Duke Human Vaccine Institute
- Sarzotti-Kelsoe, Marcella, Member of the Duke Human Vaccine Institute
- Saunders, Kevin O'Neil, Member of the Duke Human Vaccine Institute
- Sempowski, Gregory David, Member of the Duke Human Vaccine Institute
- Shen, Xiaoying, Member of the Duke Human Vaccine Institute
- Sleasman, John William, Member of the Duke Human Vaccine Institute
- Spicer, Leonard D., Member of the Duke Human Vaccine Institute
- Staats, Herman Ford, Member of the Duke Human Vaccine Institute
- Steinbach, William J., Member of the Duke Human Vaccine Institute
- Swamy, Geeta Krishna, Member of the Duke Human Vaccine Institute
- Thompson, Amelia B, Member of the Duke Human Vaccine Institute
- Tomaras, Georgia Doris, Member of the Duke Human Vaccine Institute
- Verkoczy, Laurent Karl, Member of the Duke Human Vaccine Institute
- Walter Jr., Emmanuel Benjamin, Member of the Duke Human Vaccine Institute
- Weinhold, Kent James, Member of the Duke Human Vaccine Institute
- Wiehe, Kevin J, Member of the Duke Human Vaccine Institute
- Williams, Wilton Bryan, Member of the Duke Human Vaccine Institute
-
Non-Faculty Positions
- Hwang, Kwan-Ki, Research Scientist, Senior
-
-
Administers Grant
- CISA 2018-2019 - Clinical Consult - Base
- A Magnetic Microparticle Kit for Cell Removal from Blood
- A tailored school-based intervention to increase vaccine uptake among adolescents in the rural South
- Animal Models of Infectious Diseases Part A
- Antibody and viral determinants of protection against CMV infection following gB/MF59 vaccination
- Antibody and viral determinants of protection against CMV infection following gB/MF59 vaccination
- Antibody protection against SIV transmission
- Automated detection of protein crystals in high-throughput crystallography experiments
- Avioq _VioOne HIV Profile Supplement Assay Project
- B-cell repertoire analysis in influenza vaccination and infection - Project 1
- Bridging Antibody Fc-mediated Antiviral Functions Across Humans and Non-human Primates
- Broad neutralizing antibodies against HIV-1 from RV217 participants
- CARE Duke-UNC Latency Biomarker Supplement Year 2
- CISA - 2017 TO# 07 - TDAP IIV in Pregnant Women (LEAD) Logical Follow-On - Option 1
- CISA - 2017 TO# 07 - TDAP IIV in Pregnant Women (LEAD) Logical Follow-On - Option 2
- CISA - 2017 TO# 07 - TDAP IIV in Pregnant Women (LEAD) Logical Follow-On - Option 3
- CISA 2017 06 - Clinical Consult - Base
- CISA 2017 06 - Clinical Consult - Opt 2
- CISA 2018-2019 - Clinical Consult - Opt 2
- CISA 2018-2019- Clinical Consult - Opt 1
- CISA Clinical Consult TO I - Option 4
- CISA RFTP 2017-03 Syncope Prevention Study (Lead) - Base
- CISA RFTP 2017-03 Syncope Prevention Study (Lead) - Option 1
- CISA RTOP 2017-01 Apnea (Lead) - Base
- CISA RTOP 2017-01 Apnea (Lead) - Option 1
- CISA TO2 Prophylactic Antipyretics Revision 1-A
- CISA TO2 Prophylactic Antipyretics Revision 3-A
- CISA Task Order No. 3 Tdap Safety in Pregnant Women
- CISA Task Order No. 3 Tdap Safety in Pregnant Women Infant Option Task 1-CLIN0002
- CISA Task Order No. 3 Tdap Safety in Pregnant Women Infant Option Task 2-CLIN0003
- CISA: 2015 CISA 02 - Contributing Site Base Task: Consultation for the LAIV and Asthma Study (Contributing)
- CISA: 2015 CISA 02 - Contributing Site Optional Task 1: Enrollment and Data Collection for the LAIV and Asthma Study (Contributing)
- CISA: 2015 CISA 03 - Lead Site Base Task: Maternal Tdap and IIV Study (Lead)
- CISA: 2015 CISA 03 - Lead Site Optional Task 1: Additional Subjects for Maternal Tdap and IIV Study (Lead)
- Characterization BCG-Gag immunized macaques
- Chronic Fatigue Initiative Bio-Bank
- Collaboratory of AIDS Researchers for Eradication - Management and Operations
- Comprehensive T cell Vaccine Immune Monitoring Consortium (CTVIMC)
- Core C: Monitoring Host Response
- Core D: Human Translation and Verification
- Creation of a bnAbnectin
- Critical domains for HIV-1 entry through atypical coreceptor usage
- Defining and Redirecting Influenza Immunity After Imprinting
- Defining parameters to induce breadth in knockin mice expressing HIV bnAb precursors
- Defining parameters to induce breadth in knockin mice expressing HIV bnAb precursors
- Development of a nonhuman primate model of fetal Zika virus infection and disease
- Development of broadly neutralizing antibody responses in HIV-infected children
- Duke Clinical Good Manufacturing Practices Facility for HIV/AIDS Vaccine Production
- Duke DARPA Pandemic Prevention Platform (P3)
- Duke Infectious Disease Response Training Consortium (DIDRT)
- EQAPOL
- EQAPOL - 2016 to 2017 - Option 6 - BASE
- EQAPOL - 2016 to 2017 - Option 6 - FLOW
- EQAPOL - 2016 to 2017 - Option 6 - VIRUS
- EQAPOL - Option 48 - 2016 to 2017 - A3R5
- EQAPOL - Option 48 - 2016 to 2017 - LUMINEX
- EQAPOL - Option 6 - 2016 to 2017 - ELISPOT
- EQAPOL - Years 2017 to 2024 - BASE
- EQAPOL Option 47
- EQAPOL Option 5
- Early Infection Response
- Early Rota Merck MISP
- Enhancing protective antibody responses for a GM-CSF adjuvanted HIV vaccine
- Epigenetic Control of the CD8+ T-cell Response to HIV
- Eqapol Opt 1 -2018-2019
- Experimental Human Infection with Isogenic Mutants of Neisseria gonorrhoeae
- Focus 1: Detection of HIV Antigen-Positive Cells
- Focus 2: Clearance of HIV Antigen-Positive Cells
- Functional profile to HIV vaccine elicited antibodies in infants
- Gut Bacteria Prime B cells towards gp120-specific response in African Green Monkeys.
- HIV Research for Prevention 2018: Vaccine, Microbicide and ARV-based Prevention Science (HIVR4P)
- HIV-1 vaccine-elicited antibodies target envelope glycans
- Harnessing Antibody-Mucus Interaction to Prevent HIV Transmission
- Harnessing Mucin-IgG Interactions to Enhance HIV Vaccine Function
- Humoral and cellular immunity during acute HIV-1
- Hyperimmune globulin treatment of Zika virus during pregnancy to reduce Congenital Zika Syndrome
- IQA Option 18 - UK NEQAS Proficiency Testing Cryo
- IQA Option 25 -PBMC Cryopreservation Proficiency Testing
- IQA Option 4
- Identifying key determinants of IgG transplacental transfer from HIV-infected mothers to their fetus
- Identifying key determinants of IgG transplacental transfer from HIV-infected mothers to their fetus
- Identifying maternal immune correlates of protection against perinatal mother-to-child transmission (MTCT)
- Immunogen Design of HIV Sequential Envelopes Derived from SHIV-infected Macaques
- Immunology Quality Assesment Program Option 2
- Immunology Quality Assesment Program Options 1-6
- Immunology Quality Assessment Program - Option 41
- Immunology Quality Assessment Program Option 3
- Immunology Quality Assessment Program Year 5
- Indexus Contract
- Infant immune correlates of perinatal mother to child transmission of HIV
- Innate antiviral factors in breast milk and the oral HIV-1 reservoir
- International Maternal Pediatric Adolescent AIDS Clinical Trial (IMPAACT) Group
- Isolation of protective ZIKV-neutralizing maternal monoclonal antibodies for safe prophylactic use in the preconception period
- LOC-IMPAACT Leadership Group
- Letvin Gates Mycobacteria Grant
- Maternal and infant immunization to eliminate breast milk transmission of HIV-1
- Maternal immune protection against congenital CMV infection
- McElrath Objective 3-Evaluate potential mucosal quality indicators
- McElrath Objective 3-Evaluate potential mucosal quality indicators
- Mechanisms of Age Induced Thymic Atrophy
- Mycobacterial Genes Responsible for Regulating Autophagy
- NSF Grad Res Fellowship Prog Perley
- Neonatal Immunity to novel TF SHIVs
- Non-human Primate Binding Antibody Evaluation
- Nonhuman Primate Core Virology Laboratory for AIDS Vaccine Research and Development - Base
- Nonhuman Primate Core Virology Laboratory for AIDS Vaccine Research and Development - Option 7-13
- Novel mouse model of HIV broad neutralizing antibody induction
- Option Three (3) of Contract No. 200-2012-53663, Task Order 0001
- P186 Research Analysis
- PRO HIV-013 Humoral Immune Response
- Permar IMPAACT 2004 stability study QAU
- Production of HIV-1 Envs #2
- RERF year 7 funding
- RFTP 2016 CISA 01 - Base - FLUAD vs. Fluzone® High-Dose Study (Lead)
- RFTP 2016 CISA 03 - Base - Fever after simultaneous vaccination (Lead)
- RFTP 2016 CISA 03 - Option 1 - Fever after Simultaneous Vaccination (Lead)
- RFTP 2018 CISA 05 FLUAD Logical Follow On Task 1
- RTOP 2018 CISA 01 Flublok Lead Base
- RTOP 2018 CISA 01 Flublok Lead Task 1
- Rapid, Near Patient Nucleic Acid Testing for Infant Cytomegalovirus (CMV) Infection
- Recombinant vectored delivery of maternal antibody for transfer into breast milk and across the placenta
- Role of neutralizing antibodies in HIV-1-infected and vaccinated mothers in MTCT
- SE STI CRC Core C: Immunology
- SIV-specific immunity in breast milk during infection and after vaccination
- SRA - EQAPOL Luminex Program - CSL Limited
- SRA - EQAPOL Luminex Program - Peter MacCallum Cancer Centre
- Screening CMV-specific rhesus mab for neutralizing function
- Simple interventions to Improve Rotavirus Vaccine Effectiveness (SIRVE)
- Statistical methods for HIV-1 immune correlates studies
- Statistical methods for HIV-1 immune correlates studies
- Structure-function Analysis of Infection and Vaccine Induced B-Cell Reoertiures-Supplement
- Subcontract from UAB for Tetramer Production
- Testing the ability of antibody-mucin interactions to provide vaccine function
- The B cell repertoire and antibody maturation elicited by adjuvanted HIV envelope vaccines in infants
- The duality of vaccine elicited HIV specific-IgA antibodies: Providing protection or diminishing protection
- The origin, predictors, and immune correlates of viral rebound in orally SHIV infected infant monkeys
- The relationship between maternal ZIKV-specific and ADE antibodies and fetal outcome
- Transmission-blocking potential of novel HIV Env-specific mucosal antibodies
- UNC CETR Core D: Immunology/Influenza Virology
- VTEU 12-0016: Task Area C: Protocol implementation
- VTEU 12-0021 - Task C Option 1
- VTEU 12-0021 Task C - Base
- VTEU 13-0053 Task Area B
- VTEU 13-0053 Task Area C
- VTEU A-1 Admin
- VTEU FY.2018.A1B1C1D1.0077 - Task A - Option 1
- VTEU FY.2018.A1B1C1D1.0077 Task Area A - Base
- VTEU RTOP 16-0027.C1D1.0079 - Task Area C Base
- VTEU RTOP 16-0027.C1D1.0079 - Task Area D-Option 3
- VTEU RTOP FY.2017.B8C12.0080 - Task B
- VTEU RTOP FY.2017.B8C12.0080 - Task C - Option 1
- VTEU RTOP FY.2017.B8C12.0080 - Task C - Option 3
- VTEU RTOP FY.2017.B8C12.0080 - Task C - Option 8
- VTEU RTOP FY.2019.A1B1C1D1.0103 - Task A - Base
- VTEU Sample Task Orders
- VTEU Task A Base - FY.2017.A1B1C1D1.0048
- VTEU Task A Option 1 - FY.2017.A1B1C1D1.0048
- VTEU Task A Protocol FY.2015.A4D14.0033
- VTEU Task Area A - FY.2015.A1.0016 Base
- VTEU Task Area A, Base Protocol FY.2016.A1.0026
- VTEU Task Area B Option 2 Protocol FY.2016.B1.0026
- VTEU Task Area B Option 2 Protocol FY.2016.B1.0026
- VTEU Task Area B Protocol 15-0020.B1C1.0040
- VTEU Task Area C Option 1 Protocol 15-0020.B1C1.0040
- VTEU Task Area C Option 2-1 Protocol 15-0020.B1C1.0040
- VTEU Task Area C Option 3 Protocol FY.2016.C1.0026
- VTEU Task Area C Option 3B Protocol FY.2016.C1.0026
- VTEU Task Area C: Protocal implementation for protocal # 13-0020
- VTEU Task Area D Option 8 Protocol FY.2016.D1.0026
- VTEU Task Area D Option 8B Protocol FY.2016.D1.0026
- VTEU Task Area D Option 9 Protocol FY.2016.D1.0026
- VTEU Task B - FY.2017.B2C2D2.0053
- VTEU Task B Base Protocol 14-0079.B1C1.0028
- VTEU Task B Base Protocol 15-0066.B1C1D1.0041
- VTEU Task B Option 2 - FY.2017.A1B1C1D1.0048
- VTEU Task C Base Protocol 14-0024.C1D1.0037
- VTEU Task C Option 1 - FY.2017.B2C2D2.0053
- VTEU Task C Option 1 Protocol 14-0024.C1D1.0037
- VTEU Task C Option 1 Protocol 14-0079.B1C1.0028
- VTEU Task C Option 1 Protocol 15-0066.B1C1D1.0041
- VTEU Task C Option 2 - FY.2017.B2C2D2.0053
- VTEU Task C Option 2 Protocol 14-0079.B1C1.0028
- VTEU Task C Option 3 - FY.2017.B2C2D2.0053
- VTEU Task C Option 4 - FY.2017.B2C2D2.0053
- VTEU Task D Option 1 Protocol FY.2015.A4D14.0033
- VTEU Task D Option 2 Protocol 14-0024.C1D1.0037
- VTEU Task D Option 2 Protocol FY.2015.A4D14.0033
- VTEU Task D Option 3 Protocol 14-0024.C1D1.0037
- VTEU Task D Option 3 Protocol FY.2015.A4D14.0033
- VTEU Task D Option 4 Protocol 14-0024.C1D1.0037
- VTEU Task D Option 4 Protocol FY.2015.A4D14.0033
- VTEU Task D Option 5 - FY.2017.B2C2D2.0053
- VTEU Task D Option 5 Protocol 14-0024.C1D1.0037
- VTEU Task D Option 6 - FY.2017.B2C2D2.0053
- VTEU Task D Protocol FY.2015.D1B1C1.0032
- VTEU Task Order 13-0045.C1D1.0062 - Task C Option 1
- VTEU Task Order 13-0045.C1D1.0062 - Task D
- VTEU Task Order 16-0047 -Task C Option 1
- VTEU Task Order 16-0047.C1.0090
- VTEU Task Order 16-0058 - Task B
- VTEU Task Order 16-0058 - Task C
- VTEU Task Order 16-0058.B1C1D1.0076 - Task D
- VTEU: Base -Task Area A: Project Logistics and Site Activation Protocol #14-0053
- VTEU: Option 1-Task Area B: Protocol Development Protocol #14-0053
- VTEU: Task Area C: Protocol Implementation - Option 2 Protocol #14-0053
- VTEU: Task Area D: Research Laboratory Analysis Protocol #14-0053
- Vaccine-induced HIV antibody responses in infants
- Virology Core
- Whole genome sequencing of 100 high risk, uninfected individuals
- Whole genome sequencing of rhesus macaques